Pembrolizumab + Lenvatinib + Placebo for lenvatinib
Phase 3Completed 0 watching 0 views this week📈 Rising
77
Development Stage
✓
Pre-clinical✓
Phase 1✓
Phase 24
Phase 35
ApprovedIndication / Disease
Malignant Melanoma
Conditions
Malignant Melanoma
Trial Timeline
Jul 14, 2020 → Nov 1, 2024
NCT ID
NCT04889118About Pembrolizumab + Lenvatinib + Placebo for lenvatinib
Pembrolizumab + Lenvatinib + Placebo for lenvatinib is a phase 3 stage product being developed by Eisai for Malignant Melanoma. The current trial status is completed. This product is registered under clinical trial identifier NCT04889118. Target conditions include Malignant Melanoma.
Hype Score Breakdown
Clinical
27
Activity
18
Company
10
Novelty
9
Community
10
Clinical Trials (5)
| NCT ID | Phase | Status |
|---|---|---|
| NCT04889118 | Phase 3 | Completed |
| NCT04676412 | Phase 3 | Completed |
| NCT03898180 | Phase 3 | Completed |
| NCT03829332 | Phase 3 | Completed |
| NCT03820986 | Phase 3 | Completed |
Competing Products
20 competing products in Malignant Melanoma